What is Core Biogenesis?
Core Biogenesis operates at the intersection of synthetic biology and industrial manufacturing. The company specializes in a proprietary platform technology that utilizes plant oleosomes to stabilize and produce recombinant proteins. This innovative approach offers a sustainable and scalable alternative to traditional bioreactor-based production methods, which are often energy-intensive and costly. By targeting the Life Science and Beauty & Wellness sectors, Core Biogenesis addresses the critical demand for high-purity, cost-effective protein ingredients. Their market position is defined by a commitment to sustainable bioproduction, effectively bridging the gap between laboratory-scale innovation and industrial-grade output for global health and wellness applications.
How much funding has Core Biogenesis raised?
Core Biogenesis has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2022): $10.5M with participation from XAnge, Thia Ventures, and Blue Horizon Ventures
Key Investors in Core Biogenesis
XAnge
XAnge is a European early-stage venture capital firm with €700M AUM, dedicated to empowering visionary founders from Seed to Series B with capital and expertise.
Thia Ventures
Thia Ventures is a fund management company that focuses on investments at the intersection of food, biotechnology, and health, operating under a Capital Markets Services license.
Blue Horizon Ventures
Blue Horizon Ventures is a food technology-focused venture capital fund that supports the movement towards a more sustainable food system through innovation and cellular agriculture.
What's next for Core Biogenesis?
With the successful closure of this major strategic investment, Core Biogenesis is well-positioned to scale its manufacturing infrastructure and expand its commercial footprint. The company's roadmap likely involves deepening its penetration into the regenerative medicine space while simultaneously diversifying its portfolio within the high-growth longevity skincare market. Future growth will be predicated on the company's ability to maintain protein stability at scale and secure long-term partnerships with major pharmaceutical and cosmetic manufacturers. As the firm matures, the focus will shift toward optimizing supply chain efficiencies and navigating the regulatory landscapes governing plant-derived biological products, ensuring that their sustainable bioproduction model remains competitive against conventional synthetic alternatives.
See full Core Biogenesis company page
